Date: 2014-03-20
Type of information: Private placement
Company: Nanobiotix (France)
Investors:
Amount: € 28.1 million
Funding type: private placement
Planned used: This capital increase will provide Nanobiotix additional funds to support NBTXR3 development. Last February, the company has announced positive results from the pilot phase of NBTXR3 in patients with advanced soft tissue sarcoma. So NBTXR3 could be CE marked as early as 2016,and the company intends to begin the product registration phase (pivotal) in late 2014. Nanobiotix also continues to progress the clinical development of NBTXR3 in elderly patients with head and neck cancers through 2014. In 2014, Nanobiotix will pursue its partnership policy for the development and market access of NBTXR3 outside Europe. For its development in Asia, Nanobiotix signed its first licensing contract of up to US$57 million with the Taiwanese company, PharmaEngine, in August 2012, to cover the development and commercialization of NBTXR3 in the Asia-Pacific region. This program is expected to start in H2 2014 with two indications, advanced rectal cancer and advanced mouth cancer. For NBTXR3’s development and commercialisation in the United States, Nanobiotix is investigating the possibility of partnering the product in 2014.In Europe, the Company will focus on market access and the preparation for a commercial launch of NBTXR3.
Others: * On March 20, 2014, Nanobiotix has announced the success of its capital increase with retention preferential subscription rights launched on 25 February 2014. The gross amount of the transaction amounts to €28.1 million for a total demand of about €44.1 million euros (or a subscription rate of 181 %). 2,650,390 new shares were subscribed at a price of €10.60.
Therapeutic area: Cancer - Oncology
